Mineralys Therapeutics Inc (MLYS)

Mar 29, 2025, 2:30 PM EDT - 5 days ago

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

Mar 25, 2025, 8:00 AM EDT - 9 days ago

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Mar 18, 2025, 4:01 PM EDT - 16 days ago

Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Mar 17, 2025, 8:00 AM EDT - 17 days ago

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo

Mar 12, 2025, 8:36 AM EDT - 22 days ago

Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

LDI MOMO

Mar 11, 2025, 10:20 PM EDT - 23 days ago

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

Mar 10, 2025, 6:25 PM EDT - 24 days ago

Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts

Mar 10, 2025, 4:01 PM EDT - 24 days ago

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Mar 10, 2025, 1:50 PM EDT - 24 days ago

Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate

Mar 10, 2025, 1:09 PM EDT - 24 days ago

Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher

Mar 10, 2025, 7:12 AM EDT - 24 days ago

Mineralys Therapeutics' blood pressure drug meets goal in trials

Mar 10, 2025, 7:00 AM EDT - 24 days ago

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Mar 7, 2025, 4:01 PM EST - 27 days ago

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Feb 12, 2025, 1:38 PM EST - 7 weeks ago

Mineralys Therapeutics, Inc. (MLYS) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 7:00 AM EST - 7 weeks ago

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 5, 2025, 4:05 PM EST - 2 months ago

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

Jan 19, 2025, 8:18 PM EST - 2 months ago

Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension

Nov 11, 2024, 10:00 PM EST - 5 months ago

Mineralys Therapeutics, Inc. (MLYS) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:05 PM EST - 5 months ago

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 4:05 PM EST - 5 months ago

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

Nov 4, 2024, 4:05 PM EST - 5 months ago

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024

Oct 24, 2024, 11:00 AM EDT - 5 months ago

The Schall Law Firm Invites Investors To Join An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud

Oct 22, 2024, 11:00 AM EDT - 5 months ago

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud

Oct 20, 2024, 11:00 AM EDT - 5 months ago

The Schall Law Firm Encourages Investors To Join An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud

Oct 18, 2024, 11:00 AM EDT - 5 months ago

The Schall Law Firm Encourages Investors To Take Part In An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud

Oct 16, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics Inc For Securities Fraud

Oct 14, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Encourages Investors To Take Part In An Inquiry Into Mineralys Therapeutics Inc For Possible Securities Fraud

Oct 10, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics Inc For Possible Securities Fraud

Oct 2, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Invites Investor Participation In An Inquiry Into Mineralys Therapeutics Inc For Possible Securities Fraud

Sep 29, 2024, 11:00 AM EDT - 6 months ago

Mineralys Therapeutics, Inc. Is Being Investigated For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm

Sep 28, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Invites Investor Participation In An Inquiry Into Mineralys Therapeutics Inc For Securities Related Infractions

Sep 27, 2024, 11:00 AM EDT - 6 months ago

Mineralys Therapeutics, Inc. Is Being Investigated For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Sep 25, 2024, 11:00 AM EDT - 6 months ago

Mineralys Therapeutics, Inc. Is Being Investigated For Securities Fraud And Shareholders Are Urged To Help The Schall Law Firm

Sep 25, 2024, 8:00 AM EDT - 6 months ago

Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension

Sep 24, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Invites Investors To Join An Inquiry Into Mineralys Therapeutics Inc For Violating Securities Laws

Sep 24, 2024, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mineralys Therapeutics, Inc. (MLYS) and Encourages Shareholders to Learn More About the Investigation

Sep 23, 2024, 11:00 AM EDT - 6 months ago

Mineralys Therapeutics, Inc. May Have Defrauded The Public And Shareholders Are Urged To Help The Schall Law Firm Investigate

Sep 23, 2024, 10:00 AM EDT - 6 months ago

Mineralys Therapeutics, Inc. (MLYS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Sep 22, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Seeks Investor Participation In An Inquiry Into Mineralys Therapeutics Inc For Violating Securities Laws

Sep 22, 2024, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Mineralys Therapeutics, Inc. (MLYS) Shareholders to Inquire about Securities Investigation

Sep 21, 2024, 11:00 AM EDT - 6 months ago

Mineralys Therapeutics, Inc. Is Being Investigated By The Schall Law Firm For Securities Fraud And Stakeholders Are Urged To Contribute

Sep 20, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Has Launched An Inquiry Into Mineralys Therapeutics Inc For Violating Securities Laws And Affected Investors Should Reach Out